According to the Zhitong Finance App, Luye Pharmaceutical (02186) announced its 2025 results. Revenue increased 4.1% year on year to 6.308 billion yuan, profit attributable to shareholders was about 619 million yuan, up 31.12% year on year; basic profit per share was 15.88 points.

The announcement stated that the increase in revenue was due to increased sales and licensing revenue for a number of products.

The company said that the group will simultaneously focus on rapid release of new products, forward-looking layout and timely optimization of innovative research and development, and cost efficiency improvements to achieve long-term sustainable growth in revenue and profit, and create short- and long-term value returns for the Group's shareholders.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.